So Nakamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
So Nakamura has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Yasuhisa Mori
Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
4 shared publications- Kazuhiro Matsumoto
Department of Urology Keio University School of Medicine Tokyo Japan
3 shared publications - Masafumi Nakamura
Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University
3 shared publications - Nobuyuki Tanaka
Department of Urology, Keio University School of Medicine
3 shared publications Nozomi Hayakawa
Department of Urology, Saiseikai Central Hospital, Tokyo, Japan
3 shared publications- Takao Ohtsuka
Department of Digestive Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
3 shared publications
Latest Publications
- Open Access
- 10 April 2020
- Published by Springer Nature in Surgical Case Reports
- Vol. 6 (1) , 1-5
Intramural metastasis to the appendix from ascending colon cancer: a case report
Background: Intramural metastasis is rare in colorectal cancer, especially metastasis of ascending colon cancer to the appendix. Case presentation: A 64-year-old man was admitted to our hospital for surgery for ascending colon cancer detected by medical examination. Colonoscopy identified a type-2 tumor in the ascending colon, which was diagnosed as adenocarcinoma. Abdominal computed tomography revealed focal thickening of the ascending colon and middle of the appendix and swelling of the lymph nodes around the ileocolic artery. The patient underwent laparoscopic right hemi-colectomy with D3 lymph node dissection. Histopathological findings revealed that the ascending colon cancer was moderately differentiated adenocarcinoma with lymphatic and vascular invasion (stage IIIB; pT3N2M0). Additionally, moderately differentiated adenocarcinoma was observed mainly in the submucosa and muscularis propria of the appendix, which was approximately 10 cm proximal to the ascending colon cancer. These findings indicated intramural metastasis to the appendix from the ascending colon cancer. The patient experienced recurrence with lung metastasis 2.5 years after the first surgery. Conclusions: Intramural metastasis of ascending colon cancer to the appendix is extremely rare. Because the risk of recurrence and the prognosis for intramural metastasis has not been clarified, careful follow-up is recommended.
- 10 April 2020
- Published by Springer Nature in Surgical Case Reports
- Vol. 6 (1) , 1-5
Open AccessIntramural metastasis to the appendix from ascending colon cancer: a case report
Background: Intramural metastasis is rare in colorectal cancer, especially metastasis of ascending colon cancer to the appendix. Case presentation: A 64-year-old man was admitted to our hospital for surgery for ascending colon cancer detected by medical examination. Colonoscopy identified a type-2 tumor in the ascending colon, which was diagnosed as adenocarcinoma. Abdominal computed tomography revealed focal thickening of the ascending colon and middle of the appendix and swelling of the lymph nodes around the ileocolic artery. The patient underwent laparoscopic right hemi-colectomy with D3 lymph node dissection. Histopathological findings revealed that the ascending colon cancer was moderately differentiated adenocarcinoma with lymphatic and vascular invasion (stage IIIB; pT3N2M0). Additionally, moderately differentiated adenocarcinoma was observed mainly in the submucosa and muscularis propria of the appendix, which was approximately 10 cm proximal to the ascending colon cancer. These findings indicated intramural metastasis to the appendix from the ascending colon cancer. The patient experienced recurrence with lung metastasis 2.5 years after the first surgery. Conclusions: Intramural metastasis of ascending colon cancer to the appendix is extremely rare. Because the risk of recurrence and the prognosis for intramural metastasis has not been clarified, careful follow-up is recommended.
- 28 February 2019
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 26 (7) , 2104-2111
Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma
Background Pancreatic ductal adenocarcinoma (PDAC) is a lethal neoplasm because of difficulties in early detection. Several studies have recently suggested that exosomes may have potential as novel...
- 28 February 2019
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 26 (7) , 2104-2111
Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma
Background Pancreatic ductal adenocarcinoma (PDAC) is a lethal neoplasm because of difficulties in early detection. Several studies have recently suggested that exosomes may have potential as novel...
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1 (1) , AB104
AB104. P078. Exosomal microRNAs in pancreatic juice have possibility as biomarkers to detect pancreatic ductal adenocarcinoma
Background: Because pancreatic ductal adenocarcinoma (PDAC) is a lethal neoplasm which is often diagnosed late due to difficult early detection, it is crucial to devise biomarkers to detect PDAC. Exosomes are small membrane vesicles secreted from various cells and identified in several body fluids. Recently, some studies have indicated exosomes have a potential to become novel biomarkers. This study aimed to prove the existence of exosomes in pancreatic juice (PJ) and investigate whether exosomal microRNAs (ex-miRs) could be used as biomarkers for PDAC. Methods: PJ was collected by endoscopic retrograde pancreatography in patients with PDAC and chronic pancreatitis (CP). The ultracentrifuge method was applied to extract the exosomes. Relative expression levels of ex-miR21 and ex-miR155 were quantified and their expression levels were compared between PDAC and CP. Results: A total of 35 PJ samples (27 PDACs and 8 CPs) were collected. Presence of exosomes in PJ was determined by electronic microscope and western blot using anti-CD63, CD81, and TSG101 antibody. Relative expression levels of ex-miR21 and ex-miR155 were significantly higher in PDAC than in CP (PConclusions: Ex-miR21 and ex-miR155 in PJ may be potential biomarkers for PDAC.
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1 (1) , AB104
AB104. P078. Exosomal microRNAs in pancreatic juice have possibility as biomarkers to detect pancreatic ductal adenocarcinoma
Background: Because pancreatic ductal adenocarcinoma (PDAC) is a lethal neoplasm which is often diagnosed late due to difficult early detection, it is crucial to devise biomarkers to detect PDAC. Exosomes are small membrane vesicles secreted from various cells and identified in several body fluids. Recently, some studies have indicated exosomes have a potential to become novel biomarkers. This study aimed to prove the existence of exosomes in pancreatic juice (PJ) and investigate whether exosomal microRNAs (ex-miRs) could be used as biomarkers for PDAC. Methods: PJ was collected by endoscopic retrograde pancreatography in patients with PDAC and chronic pancreatitis (CP). The ultracentrifuge method was applied to extract the exosomes. Relative expression levels of ex-miR21 and ex-miR155 were quantified and their expression levels were compared between PDAC and CP. Results: A total of 35 PJ samples (27 PDACs and 8 CPs) were collected. Presence of exosomes in PJ was determined by electronic microscope and western blot using anti-CD63, CD81, and TSG101 antibody. Relative expression levels of ex-miR21 and ex-miR155 were significantly higher in PDAC than in CP (PConclusions: Ex-miR21 and ex-miR155 in PJ may be potential biomarkers for PDAC.
- 1 September 2015
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 33 (9) , 386.e15-386.e21
Comparison of outcomes between ultrasonography and cystoscopy in the surveillance of patients with initially diagnosed TaG1-2 bladder cancers: A matched-pair analysis
- 1 September 2015
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 33 (9) , 386.e15-386.e21
Comparison of outcomes between ultrasonography and cystoscopy in the surveillance of patients with initially diagnosed TaG1-2 bladder cancers: A matched-pair analysis
- 25 June 2013
- Published by Springer Nature in Medical Oncology
- Vol. 30 (3) , 647
The type of patients who would benefit from anti-androgen withdrawal therapy: could it be performed safely for aggressive prostate cancer?
This study was designed to detect the factors that were significantly associated with the results of anti-androgen withdrawal (AAWD) therapy, and to examine whether patients with aggressive prostate cancer demonstrating a short prostate-specific antigen (PSA)-doubling time (DT) could benefit from it without even greater exacerbation of the disease. We conducted a retrospective chart review study of 121 patients who received AAWD therapy due to failed combined androgen blockade (CAB) therapy. A reduction in the serum PSA level after AAWD was observed in 35 patients (28.9 %), and a greater than 50 % decrease from the baseline serum PSA level was observed in 16 patients (13.2 %). Shortening of PSA-DT after AAWD was observed in 48 patients (39.7 %). Univariate and multivariate analyses demonstrated that only a long duration of prior anti-androgen treatment was selected as a significant predictor for a good response to AAWD therapy. With respect to exacerbation after AAWD, we found that patients with a short baseline PSA-DT conversely had a low risk of subsequent shortening of PSA-DT. Using these two factors, we could stratify the patients into four groups, and patients with prior duration of anti-androgen >18 months and PSA-DT ≤3 months demonstrated the best results with a good response rate (67.9 %) and a low risk for a worsening of the disease (14.3 %). We conclude that AAWD would be effective especially for patients whose cancer progressed rapidly (short PSA-DT) after a long stable period under CAB and should be recommended before embarking on the next therapeutic maneuver.
- 25 June 2013
- Published by Springer Nature in Medical Oncology
- Vol. 30 (3) , 647
The type of patients who would benefit from anti-androgen withdrawal therapy: could it be performed safely for aggressive prostate cancer?
This study was designed to detect the factors that were significantly associated with the results of anti-androgen withdrawal (AAWD) therapy, and to examine whether patients with aggressive prostate cancer demonstrating a short prostate-specific antigen (PSA)-doubling time (DT) could benefit from it without even greater exacerbation of the disease. We conducted a retrospective chart review study of 121 patients who received AAWD therapy due to failed combined androgen blockade (CAB) therapy. A reduction in the serum PSA level after AAWD was observed in 35 patients (28.9 %), and a greater than 50 % decrease from the baseline serum PSA level was observed in 16 patients (13.2 %). Shortening of PSA-DT after AAWD was observed in 48 patients (39.7 %). Univariate and multivariate analyses demonstrated that only a long duration of prior anti-androgen treatment was selected as a significant predictor for a good response to AAWD therapy. With respect to exacerbation after AAWD, we found that patients with a short baseline PSA-DT conversely had a low risk of subsequent shortening of PSA-DT. Using these two factors, we could stratify the patients into four groups, and patients with prior duration of anti-androgen >18 months and PSA-DT ≤3 months demonstrated the best results with a good response rate (67.9 %) and a low risk for a worsening of the disease (14.3 %). We conclude that AAWD would be effective especially for patients whose cancer progressed rapidly (short PSA-DT) after a long stable period under CAB and should be recommended before embarking on the next therapeutic maneuver.
- Open Access
- 10 May 2012
- Published by Wiley in BJU International
- Vol. 110 (11b) , E508-E513
Risk of subsequent tumour recurrence and stage progression in bacille Calmette‐Guérin relapsing non‐muscle‐invasive bladder cancer
Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? So far, few previous reports have analysed the risk factors for tumour recurrence and stage progression with a special focus on BCG‐relapsing disease, defined as the recurrence after achieving a disease‐free status by initial BCG instillations for 6 months. There are no guidelines outlining a specific treatment strategy for BCG‐relapsing disease, although many BCG failure cases are attributable to BCG‐relapsing disease. In this study, additional BCG instillation was shown to decrease the subsequent tumour recurrence rate against BCG‐relapsing tumours with intermediate pathological risk features; however, a BCG‐relapsing tumour with a pathologically high risk was a significant risk factor for both subsequent tumour recurrence and stage progression. This information might identify a therapeutic strategy for BCG‐relapsing tumours. OBJECTIVE: To investigate the risk of subsequent tumour recurrence and stage progression in bacillus Calmette‐Guérin (BCG)‐relapsing non‐muscle‐invasive bladder cancer, defined as recurrence after achieving a disease‐free status for 6 months. PATIENTS AND METHODS: A total of 183 patients with BCG‐relapsing tumours were treated with conservative therapy between 1985 and 2008 at our three institutions. We analysed the association between their clinicopathological parameters and subsequent tumour recurrence or stage progression. RESULTS: Additional induction courses of BCG or anticancer drug (mitomycin C or epirubicin) instillations were performed in 119 patients and 24 patients, respectively. The remaining 40 patients did not undergo any adjuvant therapy. Multivariate analysis showed that a relapsing tumour with a pathologically high risk (defined as tumours with G3 and/or pT1 and/or concomitant carcinoma in situ ) was a significant risk factor for subsequent tumour recurrence ( P = 0.002; hazard ratio [HR] 2.15). Additional BCG instillation significantly decreased the subsequent tumour recurrence rate ( P < 0.001; HR 0.41). Multivariate analysis also showed that a relapsing tumour with a pathologically high risk was also significantly associated with stage progression ( P < 0.001; HR 8.05). CONCLUSIONS: An additional course of BCG instillation might be effective in patients with BCG‐relapsing tumours with pathologically intermediate risk. Nevertheless, some patients with high‐risk pathological features developed subsequent stage progression. Such patients should be followed up closely and counselled on the need for aggressive therapeutic options, such as radical cystectomy.
- 10 May 2012
- Published by Wiley in BJU International
- Vol. 110 (11b) , E508-E513
Open AccessRisk of subsequent tumour recurrence and stage progression in bacille Calmette‐Guérin relapsing non‐muscle‐invasive bladder cancer
Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? So far, few previous reports have analysed the risk factors for tumour recurrence and stage progression with a special focus on BCG‐relapsing disease, defined as the recurrence after achieving a disease‐free status by initial BCG instillations for 6 months. There are no guidelines outlining a specific treatment strategy for BCG‐relapsing disease, although many BCG failure cases are attributable to BCG‐relapsing disease. In this study, additional BCG instillation was shown to decrease the subsequent tumour recurrence rate against BCG‐relapsing tumours with intermediate pathological risk features; however, a BCG‐relapsing tumour with a pathologically high risk was a significant risk factor for both subsequent tumour recurrence and stage progression. This information might identify a therapeutic strategy for BCG‐relapsing tumours. OBJECTIVE: To investigate the risk of subsequent tumour recurrence and stage progression in bacillus Calmette‐Guérin (BCG)‐relapsing non‐muscle‐invasive bladder cancer, defined as recurrence after achieving a disease‐free status for 6 months. PATIENTS AND METHODS: A total of 183 patients with BCG‐relapsing tumours were treated with conservative therapy between 1985 and 2008 at our three institutions. We analysed the association between their clinicopathological parameters and subsequent tumour recurrence or stage progression. RESULTS: Additional induction courses of BCG or anticancer drug (mitomycin C or epirubicin) instillations were performed in 119 patients and 24 patients, respectively. The remaining 40 patients did not undergo any adjuvant therapy. Multivariate analysis showed that a relapsing tumour with a pathologically high risk (defined as tumours with G3 and/or pT1 and/or concomitant carcinoma in situ ) was a significant risk factor for subsequent tumour recurrence ( P = 0.002; hazard ratio [HR] 2.15). Additional BCG instillation significantly decreased the subsequent tumour recurrence rate ( P < 0.001; HR 0.41). Multivariate analysis also showed that a relapsing tumour with a pathologically high risk was also significantly associated with stage progression ( P < 0.001; HR 8.05). CONCLUSIONS: An additional course of BCG instillation might be effective in patients with BCG‐relapsing tumours with pathologically intermediate risk. Nevertheless, some patients with high‐risk pathological features developed subsequent stage progression. Such patients should be followed up closely and counselled on the need for aggressive therapeutic options, such as radical cystectomy.